Thyroid Eye Disease

Tocilizumab may be treatment option for thyroid eye disease

In a retrospective analysis of patients with active thyroid eye disease (TED) resistant to intravenous corticosteroids, intravenous tocilizumab was found to be a viable treatment option. Of the 11 patients treated with a median of 5±3.2 doses, 20 eyes achieved inactivation of TED at week 16. Proptosis and diplopia response...